Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial

Clinical Trials

Volumn 7, Issue 5, 2010, Pages 597-604

  Joo, Jungnam ^a   Geller, Nancy L ^a   French, Benjamin ^b   Kimmel, Stephen E ^b   Rosenberg, Yves ^a   Ellenberg, Jonas H ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ALPHA ALLOCATION; ANALYTICAL PARAMETERS; ANTICOAGULATION; CLINICAL STUDY; CONFERENCE PAPER; GENETIC ANALYSIS; GENOTYPE; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAMPLING; TREATMENT OUTCOME;

ALGORITHMS; ANTICOAGULANTS; DRUG DOSAGE CALCULATIONS; GENOTYPE; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STATISTICS AS TOPIC; WARFARIN;

EID: 78649969067     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510381285     Document Type: Conference Paper

References (24)

1. Ansell JE Oral anticoagulant therapy - 50 years later. Arch Intern Med 1993 ; 153: 586-96.
2. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002 ; 287: 1690-98.
3. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 ; 352: 3385-93.
4. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005 ; 106: 2329-33.
5. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007 ; 116: 2563-70.
6. Caraco Y., Blotnick S., Muszkat M. CYP2C9 Genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008 ; 83: 460-70.
7. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic versus clinical protocols for warfarin intiation in orthopedic patients. J Thromb Haemost 2008 ; 6: 1655-62.
8. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993 ; 69: 236-39.
9. Verhovsek M., Motlagh B., Crowther MA, et al. Quality of anticoagulation and use of warfarin interacting medications in long-term care: a chart review. BMC Geriatr 2008 ; 8: 13.
10. Sargent DJ, Conley BA, Allegra C., Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005 ; 23: 2020-27.
11. Wang SJ Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Pharm Stat 2007 ; 6: 283-96.
12. Moyé LA, Deswal A. Trials within trials: confirmatory subgroup analyses in controlled clinical experiments. Control Clin Trials 2001 ; 22: 605-19.
13. Simon R., Wang SJ Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J 2006 ; 6: 166-73.
14. Gage BF, Eby C., Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004 ; 91: 87-94.
15. Spandorfer JM, Merli GJ Outpatient anticoagulation issues for the primary care physician. Med Clin North Am 1996 ; 80: 475-91.
16. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009 ; 360: 753-64.
17. Maitournam A., Simon R. On the efficiency of targeted clinical trials. Statist Med 2005 ; 24: 329-39.
18. Suman VJ, Dueck A., Sargent DJ Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest 2008 ; 26: 439-44.
19. Freidlin B., Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005 ; 11: 7872-78.
20. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005 ; 3: 137-45.
21. Hirsh J., Fuster V. Guide to anticoagulant therapy. part 2: oral anticoagulants. American heart association. Circulation 1994 ; 89: 1469-80.
22. Wang SJ, O'Neill RT, Hung HMJ. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007 ; 6: 227-44.
23. Alosh M., Huque MF A flexible strategy for testing subgroups and overall population. Stat Med 2009 ; 28: 3-23.
24. Šidák Z. On multivariate normal probabilities of rectangles: their dependence on correlations. Ann Math Statist 1968 ; 39: 1425-34.